Coronaviruses pp 463-468 | Cite as

An Overview of Successful TGEV Vaccination Strategies and Discussion on the Interrelationship between TGEV and PRCV

  • Mark W. Welter
  • Michelle P. Horstman
  • C. Joseph Welter
  • Lisa M. Welter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 342)


Porcine respiratory coronavirus(PRCV) is a new variant of TGE with an altered pathogenesis. PRCV multiplies mainly in tonsilar tissues and the respiratory tract. There are no enteric symptoms and in experimentally infected pigs, even the respiratory tract infection is usually asymptomatic. PRCV is spread aerogenically through herds and the significance of PRCV as a pathogen in swine has yet to be determined. Despite the differences in pathogenesis and tissue tropism, the behavior of TGEV and PRCV are closely related antigenically. PRCV induces an antibody response in pigs that cannot be distinguished from TGEV-infected pigs by conventional serological assays. PRCV sensitized animals are not protected from TGEV challenge nor is the milk antibody provided to nursing piglets completely effective in prevention of TGEV infections; thus PRCV is not a good vaccine candidate for TGEV infections. PRCV subclinical infections have led to several reported cases of enzootic TGEV in herds that had been diagnosed as TGEV immune strictly on the basis of serum neutralizing titers which were later found to be due to exposure to PRCV. Vaccination studies conducted with the Ambico, oral modified live TGEV vaccine have led to some startling new results: (1)Use of Ambico TGEV modified live vaccine has been shown to provide complete protection against subsequent PRCV challenge and (2) the effectiveness of TGEV vaccination is actually enhanced by previous exposure to PRCV (3) Weanling pigs which have passively acquired circulating TGEV neutralizing antibodies are protected from subsequent PRCV infections.


Tonsilar Tissue Swine Herd Secondary Antibody Response Gnotobiotic Piglet TGEV Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    G.R. Fitzgerald, M.W. Welter, C.J. Welter, Improving the Efficacy of Oral TGE Vaccination. Vet. Med. 81: 184–187 (1986).Google Scholar
  2. 2.
    G.R. Fitzgerald, C.J. Welter, The Effect of an Oral TGE Vaccine on Eliminating Enzootic TGE Virus from a Herd of Swine. Agri Pract.Disease Control., 11: 25–29 (1990).Google Scholar
  3. 3.
    C.J. Welter. Effective use of Vaccination in Acute and Chronic Viral Diarrhea. Minnesota Swine Herd Health Confr.(1986).Google Scholar
  4. 4.
    C.J. Welter. Strategies for a Successful Coronavirus (TGE) Vaccine for Swine. Coronaviruses, Plenum Publishing Co. 218: 551 (1987).Google Scholar
  5. 5.
    P. Porter and W. D. Allen Classes of immunoglobulins related to immunity in the pig: A review. J. Am. Vet. Med. Assoc., 160: 511 (1972).PubMedGoogle Scholar
  6. 6.
    J. A. Graham. Induction of Active Immunity to TGE in Neonatal Pigs Nursing Seropositive Dams. VM/SAC 75: 1618 (1980).Google Scholar
  7. 7.
    P. Callebaut, I. Correa, M. Pensaert, G. Jimenez, L. Enjuanes. Antigenic Differentiation between Transmissible Gastroenteritis Virus of Swine and a Related Porcine Respiratory Coronavirus. J. Gen. Virol. 69: 1725–1730 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    D. O’Toole, I. Brown, A. Bridges, S. F. Cartwright. Pathogenicity of Experimental Infection with Pneumotropic Porcine Coronavirus. Res. Vet Sci., 47: 23–29 (1989).PubMedGoogle Scholar
  9. 9.
    D. J. Paton, I. H. Brown. Sows Infected in Pregnancy with Porcine Respiratory Coronavirus Show no Evidence of Protecting their Suckling Piglets against Transmissible Gastroenteritis. Vet. Res. Comm. 14: 329–337. (1990).Google Scholar
  10. 10.
    E. Yus, M. D. Laviada, L. Moreno, J. M. Castro, J. M. Escribano, I. Y. Simarro. The Prevalence of Antibodies to Influenza and Coronaviruses amoung Fattening Pigs in Spain. J. Vet. Med. 36: 551–556. (1989).CrossRefGoogle Scholar
  11. 11.
    C. Burns, J. Ebersole and M. Allansmith. Immunoglobulin A Antibody Levels in Human Tears, Saliva and Serum. Infec. and Immunity. 36–3: 1019–1022. (1982).Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Mark W. Welter
    • 1
  • Michelle P. Horstman
    • 1
  • C. Joseph Welter
    • 1
  • Lisa M. Welter
    • 1
  1. 1.Ambico, Inc. Dallas CenterUSA

Personalised recommendations